• 1
    Abrams P, Blaivas G, Stanton L, Andersen JT. The standardization of terminology of lower urinary tract function recommended by the International Incontinence Society. Int Urogynecol J 1990; 1: 458
  • 2
    Wise B. Detrusor instability and hyperreflexia. In Cardozo L ed. Urogynaecology. New York: Churchill Livingstone, 1997: 287306
  • 3
    Castleden CM, Duffin HM. Factors influencing outcome in elderly patients with urinary incontinence and detrusor instability. Age Aging 1985; 14: 3037
  • 4
    Venn S, Mundy T. Detrusor instability. In Stanton SL, Monga AK eds, Clinical Urogynaecology. 2nd edn. London: Churchill Livingstone, 2000: 21926
  • 5
    Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52: 4725
  • 6
    Turoff JW, Bunke B, Ebner A et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity: oxybutynin versus probanthine versus placebo. J Urol 1991; 145: 8137
  • 7
    Moore KH, Day DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990; 66: 47985
  • 8
    Baigre RE, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin, is it safe? Br J Urol 1988; 62: 31922
  • 9
    Gillerg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998; 349: 28592
  • 10
    Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 9908DOI: 10.1016/s0090-4295(98)00629-3
  • 11
    Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 15515
  • 12
    Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998; 81: 428DOI: 10.1046/j.1464-410x.1998.00501.x
  • 13
    Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The international Study Group. World J Urol 1997; 15: 14451
  • 14
    Messelink EJ. Treatment of the overactive bladder with tolterodine, an new muscarinic receptor antagonist. BJU Int 1999; 83 (Suppl. 2): 4852
  • 15
    Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (Suppl. 6A): 906
  • 16
    Abrams P, Freeman R, Anderstorm C, Mattiasson A. Tolterodine, a new muscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 80110DOI: 10.1046/j.1464-410x.1998.00717.x
  • 17
    Drutz H, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 2839
  • 18
    Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. New Eng J Med 1993; 329: 3905
  • 19
    Frazer MI, Sutherst JR, Holland EFN. Visual analogue scores and urinary incontinence. Br Med J 1987; 295: 582
  • 20
    Fantyl JA, Hankins SW, Wyman JF, Choi SC, Taylor JR. Fluid loss quantification test in women with urinary incontinence: a test-retest analysis. Obstet Gynecol 1987; 70: 73943
  • 21
    Lose G, Rosenkilde P, Gammelgarrad J, Schroeder T. Pad weighing tests performed with standardized bladder volume. Urology 1988; 32: 7880


  1. Authors

H.Y. Leung, MBChB, MRCOG, FRANZCOG, FHKAM(O&G), Medical Officer.

S.K. Yip, MBChB, MRCOG, FHKAM(O&G), Associate Professor.

C. Cheon, MBChB, MRCOG, FHKAM(O&G), Senior Medical Officer.

Y.S. Liu, MBBS, MRCOG, FHKAM(O&G), Medical Officer.

J. Lau, MSc, PhD, Director.

H.K. Wong, MBBS, MRCOG, FHKAM(O&G), Consultant.

K.H. Chung, MBBS, FRACOG, FHKAM(O&G), MD, Chairman.


Xerostomia Questionnaire


visual analogue scale




per protocol.